CD8A and melanoma: In a study by Shi et al., RFA initially induced strong T cell-mediated immune responses in a murine model of colon cancer (CT26) and melanoma (B16), followed by the inhibition of the function of CD4+ and CD8+ T cells, driving a shift toward a higher regulatory T (Treg) cell to CD8+ effector T (Teff) cell ratio and up-regulating the PD-L1/PD-1 expression when combined with anti-PD-1 antibody (58).